# Allemagne – Produits pharmaceutiques – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Dapagliflozin, ATC A10BK01 für die Zeit 01.10.2026 - 30.09.2028

Acheteur : DAK-Gesundheit.  Pays : Allemagne.  CPV : 33600000.

Source: QUOTA CÔTE — https://quotacote.com/opportunites/allemagne-produits-pharmaceutiques-abschluss-einer-nicht-exklusiven-ra--809ed278-7e9e-471f-9749-6df6ba50f011
Last checked by QUOTA: 2026-08-24
Methodology: https://quotacote.com/a-propos-des-donnees

## Key facts

- Country: Allemagne [FACT]
- Deadline: 2028-08-04 [FACT]
- Last checked by QUOTA: 2026-08-24 [FACT]
- Sector (QUOTA normalisation): Santé [ANALYSIS]
- Summary: QUOTA editorial summary of the source notice [ANALYSIS]

## Entities

- geography: Allemagne
- funder: DAK-Gesundheit
- buyer: DAK-Gesundheit

## Limitations

- QUOTA republishes a normalised summary, not the tender documents themselves.
- Commercial details (source dossier, full deadline history, budget) are reserved for subscribers.